To include your compound in the COVID-19 Resource Center, submit it here.

Spark gene therapy wins unanimous FDA panel vote

On Oct. 12, FDA's Cellular, Tissue and Gene Therapy Advisory Committee voted 16-0 that the benefit-risk profile for Luxturna voretigene neparvovec from Spark Therapeutics Inc. (NASDAQ:ONCE) supports the gene therapy's approval to treat biallelic retinal pigment epithelium-specific protein 65kDa (RPE65) mutation-associated retinal

Read the full 429 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers